PA
PTGX icon

Perceptive Advisors’s Protagonist Therapeutics PTGX Stock Holding History

Perceptive Advisors’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$120M Sell
981,879
-249,000
-20% -$26M 1.81% 17
2026
Q1 		$130M Sell
1,230,879
-119,546
-9% -$10.6M 2.54% 10
2025
Q4 		$118M Buy
1,350,425
+320,291
+31% +$26.2M 2.1% 11
2025
Q3 		$68.4M Sell
1,030,134
-44,314
-4% -$2.52M 1.98% 17
2025
Q2 		$59.4M Sell
1,074,448
-16,823
-2% -$807K 2.2% 10
2025
Q1 		$52.8M Sell
1,091,271
-180,391
-14% -$7.56M 1.86% 12
2024
Q4 		$49.1M Sell
1,271,662
-102,901
-7% -$4.49M 1.35% 23
2024
Q3 		$61.9M Buy
1,374,563
+105,828
+8% +$4.28M 1.31% 27
2024
Q2 		$44M Buy
1,268,735
+274,412
+28% +$8.04M 1.06% 26
2024
Q1 		$28.8M Buy
994,323
+611,063
+159% +$16.6M 0.5% 56
2023
Q4 		$8.79M Sell
383,260
-671,013
-64% -$11.7M 0.2% 66
2023
Q3 		$17.6M Sell
1,054,273
-415,488
-28% -$8.06M 0.59% 47
2023
Q2 		$40.6M Buy
1,469,761
+504,609
+52% +$12.6M 1.18% 27
2023
Q1 		$22.2M Buy
+965,152
New +$16.2M 0.66% 42
2021
Q1 		– Sell
-203,591
Closed -$4.1M – 156
2020
Q4 		$4.1M Buy
+203,591
New +$4.38M 0.04% 124

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Perceptive Advisors's PTGX Position: Q2 2026 in Review

Perceptive Advisors reduced its Protagonist Therapeutics (PTGX) stake by 20% in Q2 2026, selling an estimated $26M and leaving 981,879 shares worth $120M. The position accounts for 1.81% of the portfolio, ranked #17.

Perceptive Advisors first reported a position in PTGX in Q4 2020 and has held it in 15 quarters since. The position peaked at $130M in Q1 2026. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Perceptive Advisors held 981,879 shares of Protagonist Therapeutics worth $120M as of Q2 2026.
  • Perceptive Advisors sold 249,000 Protagonist Therapeutics shares in Q2 2026, an estimated $26M.
  • Protagonist Therapeutics made up 1.81% of Perceptive Advisors's portfolio in Q2 2026, its #17 holding.
  • Perceptive Advisors first reported a position in Protagonist Therapeutics in Q4 2020 and has held it in 15 quarters since.
  • Perceptive Advisors's Protagonist Therapeutics position peaked at $130M in Q1 2026.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Perceptive Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.